Cargando…

Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma

Recent data suggest that glioblastomas (GBM) activate the c-MET signaling pathway and display increased levels in anti-apoptotic Bcl-2 family members. Therefore, targeting these two deregulated pathways for therapy might yield synergistic treatment responses. We applied extracellular flux analysis t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yiru, Ishida, Chiaki Tsuge, Shu, Chang, Kleiner, Giulio, Sanchez-Quintero, Maria J., Bianchetti, Elena, Quinzii, Catarina M., Westhoff, Mike-Andrew, Karpel-Massler, Georg, Siegelin, Markus D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943348/
https://www.ncbi.nlm.nih.gov/pubmed/29743557
http://dx.doi.org/10.1038/s41598-018-25802-0
_version_ 1783321605510791168
author Zhang, Yiru
Ishida, Chiaki Tsuge
Shu, Chang
Kleiner, Giulio
Sanchez-Quintero, Maria J.
Bianchetti, Elena
Quinzii, Catarina M.
Westhoff, Mike-Andrew
Karpel-Massler, Georg
Siegelin, Markus D.
author_facet Zhang, Yiru
Ishida, Chiaki Tsuge
Shu, Chang
Kleiner, Giulio
Sanchez-Quintero, Maria J.
Bianchetti, Elena
Quinzii, Catarina M.
Westhoff, Mike-Andrew
Karpel-Massler, Georg
Siegelin, Markus D.
author_sort Zhang, Yiru
collection PubMed
description Recent data suggest that glioblastomas (GBM) activate the c-MET signaling pathway and display increased levels in anti-apoptotic Bcl-2 family members. Therefore, targeting these two deregulated pathways for therapy might yield synergistic treatment responses. We applied extracellular flux analysis to assess tumor metabolism. We found that combined treatment with ABT263 and Crizotinib synergistically reduces the proliferation of glioblastoma cells, which was dependent on dual inhibition of Bcl-2 and Bcl-xL. The combination treatment led to enhanced apoptosis with loss of mitochondrial membrane potential and activation of caspases. On the molecular level, c-MET-inhibition results in significant energy deprivation with a reduction in oxidative phosphorylation, respiratory capacity and a suppression of intracellular energy production (ATP). In turn, loss of energy levels suppresses protein synthesis, causing a decline in anti-apoptotic Mcl-1 levels. Silencing of Mcl-1 enhanced ABT263 and MET-inhibitor mediated apoptosis, but marginally the combination treatment, indicating that Mcl-1 is the central factor for the induction of cell death induced by the combination treatment. Finally, combined treatment with BH3-mimetics and c-MET inhibitors results in significantly smaller tumors than each treatment alone in a PDX model system of glioblastoma. These results suggest that c-MET inhibition causes a selective vulnerability of GBM cells to Bcl-2/Bcl-xL inhibition.
format Online
Article
Text
id pubmed-5943348
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-59433482018-05-14 Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma Zhang, Yiru Ishida, Chiaki Tsuge Shu, Chang Kleiner, Giulio Sanchez-Quintero, Maria J. Bianchetti, Elena Quinzii, Catarina M. Westhoff, Mike-Andrew Karpel-Massler, Georg Siegelin, Markus D. Sci Rep Article Recent data suggest that glioblastomas (GBM) activate the c-MET signaling pathway and display increased levels in anti-apoptotic Bcl-2 family members. Therefore, targeting these two deregulated pathways for therapy might yield synergistic treatment responses. We applied extracellular flux analysis to assess tumor metabolism. We found that combined treatment with ABT263 and Crizotinib synergistically reduces the proliferation of glioblastoma cells, which was dependent on dual inhibition of Bcl-2 and Bcl-xL. The combination treatment led to enhanced apoptosis with loss of mitochondrial membrane potential and activation of caspases. On the molecular level, c-MET-inhibition results in significant energy deprivation with a reduction in oxidative phosphorylation, respiratory capacity and a suppression of intracellular energy production (ATP). In turn, loss of energy levels suppresses protein synthesis, causing a decline in anti-apoptotic Mcl-1 levels. Silencing of Mcl-1 enhanced ABT263 and MET-inhibitor mediated apoptosis, but marginally the combination treatment, indicating that Mcl-1 is the central factor for the induction of cell death induced by the combination treatment. Finally, combined treatment with BH3-mimetics and c-MET inhibitors results in significantly smaller tumors than each treatment alone in a PDX model system of glioblastoma. These results suggest that c-MET inhibition causes a selective vulnerability of GBM cells to Bcl-2/Bcl-xL inhibition. Nature Publishing Group UK 2018-05-09 /pmc/articles/PMC5943348/ /pubmed/29743557 http://dx.doi.org/10.1038/s41598-018-25802-0 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Zhang, Yiru
Ishida, Chiaki Tsuge
Shu, Chang
Kleiner, Giulio
Sanchez-Quintero, Maria J.
Bianchetti, Elena
Quinzii, Catarina M.
Westhoff, Mike-Andrew
Karpel-Massler, Georg
Siegelin, Markus D.
Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
title Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
title_full Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
title_fullStr Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
title_full_unstemmed Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
title_short Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
title_sort inhibition of bcl-2/bcl-xl and c-met causes synthetic lethality in model systems of glioblastoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943348/
https://www.ncbi.nlm.nih.gov/pubmed/29743557
http://dx.doi.org/10.1038/s41598-018-25802-0
work_keys_str_mv AT zhangyiru inhibitionofbcl2bclxlandcmetcausessyntheticlethalityinmodelsystemsofglioblastoma
AT ishidachiakitsuge inhibitionofbcl2bclxlandcmetcausessyntheticlethalityinmodelsystemsofglioblastoma
AT shuchang inhibitionofbcl2bclxlandcmetcausessyntheticlethalityinmodelsystemsofglioblastoma
AT kleinergiulio inhibitionofbcl2bclxlandcmetcausessyntheticlethalityinmodelsystemsofglioblastoma
AT sanchezquinteromariaj inhibitionofbcl2bclxlandcmetcausessyntheticlethalityinmodelsystemsofglioblastoma
AT bianchettielena inhibitionofbcl2bclxlandcmetcausessyntheticlethalityinmodelsystemsofglioblastoma
AT quinziicatarinam inhibitionofbcl2bclxlandcmetcausessyntheticlethalityinmodelsystemsofglioblastoma
AT westhoffmikeandrew inhibitionofbcl2bclxlandcmetcausessyntheticlethalityinmodelsystemsofglioblastoma
AT karpelmasslergeorg inhibitionofbcl2bclxlandcmetcausessyntheticlethalityinmodelsystemsofglioblastoma
AT siegelinmarkusd inhibitionofbcl2bclxlandcmetcausessyntheticlethalityinmodelsystemsofglioblastoma